Brief: Aileron Therapeutics On Feb 29 Got Letter From Nasdaq That Co Has Regained Compliance For Continued Listing On Nasdaq
01/03/2024 21:15
March 1 (Reuters) - Aileron Therapeutics Inc ALRN.O :
* AILERON THERAPEUTICS: ON FEB 29 GOT LETTER FROM NASDAQ
THAT CO
HAS REGAINED COMPLIANCE FOR CONTINUED LISTING ON NASDAQ
Further company coverage: ALRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rein Therapeutics
See all newsBrief: Rein Therapeutics Receives U.S. FDA Fast Track Designation For Lti-03 In Idiopathic Pulmonary Fibrosis
Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Rein Therapeutics Q2 net loss narrows on lower R&D spending
Rein Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Rein Therapeutics Announces Closing Of $57.5 Million Underwritten Public Offering